FULL INTERVIEW: Ruxandra Teslo says John von Neumann would have been a worse drug developer than a mediocre biologist at Pfizer with the right data. In biology, intelligence was never the bottleneck. @RuxandraTeslo is a writer at @WorksInProgMag & @stripe. She joined @theojaffee and @schisofrenia the day after Anthropic's binder results and Moderna's phase 3, to break down what both actually showed: 00:47 what Claude did and didn't do on 14 of 15 targets 03:04 the harder problem isn't designing the molecule, it's picking the target 06:23 whether protein binder design has real dual use risk 08:08 why "AGI will be hyper-persuasive" is benchmark-brained 11:40 von Neumann would be a worse drug developer than a Pfizer biologist with the right data 12:46 why Moderna jumped 148% on results she says we already knew 15:34 melanoma is the most favorable cancer you could possibly test this on 18:06 why prevention trials are so hard, and screening is the real play 21:25 the GitLab founder running experimental therapies on his own cancer 22:19 why she's most excited about AI for rare disease